Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 6INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Genitourinary 1Endocrine 1

Conditions

Lymphoma, Follicular 2Urinary Bladder Neck Obstruction 1Renal Insufficiency 1Multiple Endocrine Neoplasia Type 1 1Lower Urinary Tract Symptoms 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × mirabegron × Clear all
NCT00410514 2014-04-04

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Astellas Pharma Inc

Phase 2 Completed
200 enrolled 24 charts
EndocrineGenitourinary

Urinary Bladder Neck Obstruction, Multiple Endocrine Neoplasia Type 1, Lower Urinary Tract Symptoms

NCT00750620 2013-09-05

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Astellas Pharma Inc

Phase 1 Completed
33 enrolled
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

NCT01579461 2013-09-05

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Astellas Pharma Inc

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡